Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Authors :: Brian A. Jonas
Jorge E. Cortes
Samer K. Khaled
Giovanni Martinelli
Alexander E. Perl
Siddhartha Ganguly
Nigel H. Russell
Alwin Krämer
Hervé Dombret
Donna Hogge
Anskar Y.-H. Leung
Priyanka Mehta
Pau Montesinos
Markus P. Radsak
Simona Sica
Meena Arunachalam
Melissa Holmes
Ken Kobayashi
Ruth Namuyinga
Nanxiang Ge
Antoine Yver
Yufen Zhang
Mark J. Levis
Source :: Clinical Lymphoma Myeloma and Leukemia. 19:S221-S222
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Tools